Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Discover how FF-10101, a novel CSF1R inhibitor with unique covalent binding, reprograms tumor-associated macrophages to create an anti-tumor immune environment and enhances cancer immunotherapy.